Express Pharma
Home  »  Drug approvals  »  NATCO gets US FDA approval for Pomalidomide capsules

NATCO gets US FDA approval for Pomalidomide capsules

It is indicated for the treatment of multiple myeloma

0 330
Read Article

Natco Pharma announced that its marketing partner, Breckenridge Pharmaceutical, has received final approval for its Abbreviated New Drug Application (ANDA) for Pomalidomide Capsules, from the US Food and Drug Administration {USFDA). They are indicated for the treatment of multiple myeloma.

In addition, NATCO and Breckenridge have settled the patent litigation with Celgene (now part of Bristol-Myers Squibb) in the US district court for this product.

Celgene, sells Pomalidomide Capsules under Brand name POMALYST, in the USA market which is indicated for the treatment of patients suffering from multiple myeloma cancer.

As per industry sales data, POMALYST had annual sales of $957 million during the twelve months ending September 2020.

Leave A Reply

Your email address will not be published.

 Introducing Smart Autoinjector: Changing the paradigm of usability, cost & size
Know More?
close-image
Want to know more about "Omic's" and it's relevance?
Register Now
close-image